$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny

$alny Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000117867021000017 Filed on April 29, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$177.6M	$99.48M
YoY Change	78.5%	198.78%
Cost Of Revenue	$23.02M	$13.30M
YoY Change	73.08%	297.43%
Gross Profit	$154.5M	$86.17M
YoY Change	79.34%	187.76%
Gross Profit Margin	87.03%	86.63%
Selling, General & Admin	$146.9M	$126.8M
YoY Change	15.86%	41.46%
% of Gross Profit	95.03%	147.1%
Research & Development	$185.9M	$169.6M
YoY Change	9.63%	31.32%
% of Gross Profit	120.29%	196.78%
Depreciation & Amortization	$12.60M	$7.600M
YoY Change	65.79%	-37.7%
% of Gross Profit	8.15%	8.82%
Operating Expenses	$332.8M	$296.3M
YoY Change	12.29%	35.48%
Operating Profit	-$186.3M	-$210.2M
YoY Change	-11.37%	11.32%
Interest Expense	$32.52M	$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net	-$13.02M	$28.51M
YoY Change	-145.67%	276.74%
Pretax Income	-$199.3M	-$181.6M
YoY Change	9.71%	0.24%
Income Tax	$1.016M	$575.0K
% Of Pretax Income
Net Earnings	-$200.3M	-$182.2M
YoY Change	9.92%	0.17%
Net Earnings / Revenue	-112.8%	-183.18%
Basic Earnings Per Share	-$1.71
Diluted Earnings Per Share	-$1.71	-$1.617M
COMMON SHARES
Basic Shares Outstanding	117.1M shares	112.6M shares
Diluted Shares Outstanding	117.1M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.653B	$1.304B
YoY Change	26.72%	4.79%
Cash & Equivalents	$379.5M	$467.8M
Short-Term Investments	$1.273B	$836.3M
Other Short-Term Assets	$76.00M	$98.70M
YoY Change	-23.0%	20.81%
Inventory	$73.94M	$68.30M
Prepaid Expenses
Receivables	$110.6M	$75.57M
Other Receivables	$519.1M	$0.00
Total Short-Term Assets	$2.470B	$1.585B
YoY Change	55.86%	13.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$464.6M	$429.8M
YoY Change	8.09%	-24.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$42.68M	$19.03M
YoY Change	124.23%	-64.69%
Total Long-Term Assets	$785.2M	$694.9M
YoY Change	13.0%	11.71%
TOTAL ASSETS
Total Short-Term Assets	$2.470B	$1.585B
Total Long-Term Assets	$785.2M	$694.9M
Total Assets	$3.255B	$2.280B
YoY Change	42.8%	13.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$45.38M	$40.48M
YoY Change	12.1%	78.34%
Accrued Expenses	$280.5M	$183.2M
YoY Change	53.11%	47.88%
Deferred Revenue	$116.3M	$86.04M
YoY Change	35.21%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$494.8M	$338.8M
YoY Change	46.06%	127.07%
LONG-TERM LIABILITIES
Long-Term Debt	$191.6M	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$60.46M	$9.198M
YoY Change	557.33%	-96.81%
Total Long-Term Liabilities	$60.46M	$9.198M
YoY Change	557.33%	-97.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$494.8M	$338.8M
Total Long-Term Liabilities	$60.46M	$9.198M
Total Liabilities	$2.329B	$929.9M
YoY Change	150.47%	99.12%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.786B	-$3.909B
YoY Change	22.42%
Common Stock	$5.749B	$5.291B
YoY Change	8.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$926.2M	$1.350B
YoY Change
Total Liabilities & Shareholders Equity	$3.255B	$2.280B
YoY Change	42.8%	13.19%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$200.3M	-$182.2M
YoY Change	9.92%	0.17%
Depreciation, Depletion And Amortization	$12.60M	$7.600M
YoY Change	65.79%	-37.7%
Cash From Operating Activities	-$235.7M	-$246.2M
YoY Change	-4.27%	30.58%
INVESTING ACTIVITIES
Capital Expenditures	$17.18M	$19.62M
YoY Change	-12.43%	-55.47%
Acquisitions
YoY Change
Other Investing Activities	$4.198M	$0.00
YoY Change		-100.0%
Cash From Investing Activities	$71.35M	$113.7M
YoY Change	-37.24%	10.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$51.18M	$53.87M
YoY Change	-5.0%	-86.22%
NET CHANGE
Cash From Operating Activities	-$235.7M	-$246.2M
Cash From Investing Activities	$71.35M	$113.7M
Cash From Financing Activities	$51.18M	$53.87M
Net Change In Cash	-$117.0M	-$79.24M
YoY Change	47.71%	-125.97%
FREE CASH FLOW
Cash From Operating Activities	-$235.7M	-$246.2M
Capital Expenditures	$17.18M	$19.62M
Free Cash Flow	-$252.8M	-$265.8M
YoY Change	-4.87%	14.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001178670
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity File Number EntityFileNumber	001-36407
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	ALNYLAM PHARMACEUTICALS, INC.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0602661
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	675 West Kendall Street,
CY2021Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Henri A. Termeer Square
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2021Q1	dei	City Area Code CityAreaCode	617
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	551-8200
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	551-8200
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2021Q1	dei	Trading Symbol TradingSymbol	ALNY
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	117545040	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	379543000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	496580000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1273027000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1333182000	USD
CY2021Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	56967000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	44633000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	110626000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	102413000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	73940000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	75202000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	75980000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	62767000	USD
CY2021Q1	alny	Royalties Receivable Current RoyaltiesReceivableCurrent	500000000	USD
CY2020Q4	alny	Royalties Receivable Current RoyaltiesReceivableCurrent	500000000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	2470083000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	2614777000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	464572000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	465029000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	237213000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	241485000	USD
CY2021Q1	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	40725000	USD
CY2020Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	40725000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	42676000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	45045000	USD
CY2021Q1	us-gaap	Assets Assets	3255269000	USD
CY2020Q4	us-gaap	Assets Assets	3407061000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	45381000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	51966000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	280527000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	355909000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	38917000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	36872000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	116340000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	127207000	USD
CY2021Q1	alny	Royalty Liability Current RoyaltyLiabilityCurrent	13660000	USD
CY2020Q4	alny	Royalty Liability Current RoyaltyLiabilityCurrent	13316000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	494825000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	585270000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	288015000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	293039000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	208123000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	225094000	USD
CY2021Q1	us-gaap	Long Term Debt LongTermDebt	191590000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	191278000	USD
CY2021Q1	alny	Royalty Liability Noncurrent RoyaltyLiabilityNoncurrent	1086065000	USD
CY2020Q4	alny	Royalty Liability Noncurrent RoyaltyLiabilityNoncurrent	1058225000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	60461000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37908000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	2329079000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	2390814000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	117321000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	117321000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	116427000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	116427000	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	1173000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1164000	USD
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5747394000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5644074000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-36717000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-43622000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4785660000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4585369000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	926190000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1016247000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3255269000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3407061000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	177566000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	99476000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	23023000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13302000	USD
CY2021Q1	alny	Cost Of Collaboration Manufacturing And Royalties CostOfCollaborationManufacturingAndRoyalties	8039000	USD
CY2020Q1	alny	Cost Of Collaboration Manufacturing And Royalties CostOfCollaborationManufacturingAndRoyalties	0	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	185899000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	169571000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	126761000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	363820000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	309634000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	146859000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-186254000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-210158000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	32515000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	450000	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	5480000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	19044000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	23032000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13021000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	28512000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-199275000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-181646000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1016000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	575000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-200291000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-182221000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.71
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.62
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	117080000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112748000	shares
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-200291000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-182221000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	4045000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	6848000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	340000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-58000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-74000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6905000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4459000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-193386000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-177762000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1016247000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	47034000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	0	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	56295000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6905000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-200291000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	926190000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1438692000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	54221000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	34578000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4459000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-182221000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	1349729000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-200291000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-182221000	USD
CY2021Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	12601000	USD
CY2020Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	7613000	USD
CY2021Q1	alny	Amortization And Interest Accretion Related To Operating Leases AmortizationAndInterestAccretionRelatedToOperatingLeases	10261000	USD
CY2020Q1	alny	Amortization And Interest Accretion Related To Operating Leases AmortizationAndInterestAccretionRelatedToOperatingLeases	9393000	USD
CY2021Q1	alny	Non Cash Interest Expense On Sale Of Future Royalties NonCashInterestExpenseOnSaleOfFutureRoyalties	28184000	USD
CY2020Q1	alny	Non Cash Interest Expense On Sale Of Future Royalties NonCashInterestExpenseOnSaleOfFutureRoyalties	0	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	55690000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	34578000	USD
CY2021Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	47016000	USD
CY2020Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	24111000	USD
CY2021Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	30777000	USD
CY2020Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	660000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10709000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	32882000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1934000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	11952000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	13654000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	19958000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-66573000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-14215000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-27804000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4030000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	9060000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	9036000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-235660000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-246161000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17178000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19617000	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	345954000	USD
CY2020Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	396409000	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	438682000	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	539614000	USD
CY2021Q1	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	10650000	USD
CY2020Q1	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	9900000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	10650000	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	0	USD
CY2021Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	4198000	USD
CY2020Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	71352000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	113688000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	46977000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	53869000	USD
CY2021Q1	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	4200000	USD
CY2020Q1	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	0	USD
CY2021Q1	us-gaap	Nature Of Operations NatureOfOperations	NATURE OF BUSINESS<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June 14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2021, we launched our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy, which focuses on our planned transition to a top five biotech company, as measured by market capitalization, by the end of 2025. With </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we aim to deliver transformative rare and prevalent disease medicines for patients around the world through sustainable innovation, delivering exceptional financial performance and driving profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 31, 2021, we have four products that have received marketing approval, including one partnered product, and six late-stage investigational programs advancing towards potential commercialization. We currently generate product revenues from ONPATTRO in the U.S., Europe, Japan and in several additional countries as well as from GIVLAARI and OXLUMO in the U.S. and several countries in Europe.</span></div>
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	51177000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	53869000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3910000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-631000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-117041000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-79235000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	499046000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	549628000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	382005000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	470393000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7289000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6619000	USD
CY2021Q1	alny	Number Of Marketed Products NumberOfMarketedProducts	4	product
CY2021Q1	alny	Number Of Partnered Products NumberOfPartneredProducts	1	product
CY2021Q1	alny	Number Of Clinical Programs In Late Stages NumberOfClinicalProgramsInLateStages	6	program
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our condensed consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, the supply of our products and product candidates, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and variants thereof, and the actions taken to contain or treat it or vaccinate against it, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div>
CY2021Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	19111000	USD
CY2020Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	33542000	USD
CY2021Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	94759000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	120021000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	25300000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	14700000	USD
CY2021Q1	alny	Impairment Of Marketable Debt Securities ImpairmentOfMarketableDebtSecurities	0	USD
CY2020Q1	alny	Impairment Of Marketable Debt Securities ImpairmentOfMarketableDebtSecurities	0	USD
CY2020Q1	alny	Impairment Of Marketable Debt Securities ImpairmentOfMarketableDebtSecurities	0	USD
CY2021Q1	alny	Impairment Of Marketable Debt Securities ImpairmentOfMarketableDebtSecurities	0	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1272680000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	422000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	75000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1273027000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	20000000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1273027000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1352834000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	463000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	115000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1353182000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1333182000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1273027000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1353182000	USD
CY2021Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	53694000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	63460000	USD
CY2021Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	23593000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	16149000	USD
CY2021Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	13753000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	12693000	USD
CY2021Q1	alny	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	91040000	USD
CY2020Q4	alny	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	92302000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	379543000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	467779000	USD
CY2021Q1	us-gaap	Restricted Cash RestrictedCash	2462000	USD
CY2020Q1	us-gaap	Restricted Cash RestrictedCash	2614000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	382005000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	470393000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	6847000	USD
CY2021Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-58000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6905000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	1657000	USD
CY2020Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-2802000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4459000	USD
CY2021Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.15
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55690000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34578000	USD
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15397000	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15020000	shares

Files In Submission

Name	View Source	Status
0001178670-21-000017-index-headers.html	Edgar Link	pending
0001178670-21-000017-index.html	Edgar Link	pending
0001178670-21-000017.txt	Edgar Link	pending
0001178670-21-000017-xbrl.zip	Edgar Link	pending
alny-20210331.htm	Edgar Link	pending
alny-20210331.xsd	Edgar Link	pending
alny-20210331_cal.xml	Edgar Link	unprocessable
alny-20210331_def.xml	Edgar Link	unprocessable
alny-20210331_g1.jpg	Edgar Link	pending
alny-20210331_htm.xml	Edgar Link	completed
alny-20210331_lab.xml	Edgar Link	unprocessable
alny-20210331_pre.xml	Edgar Link	unprocessable
alny2021q110-qex311.htm	Edgar Link	pending
alny2021q110-qex312.htm	Edgar Link	pending
alny2021q110-qex321.htm	Edgar Link	pending
alny2021q110-qex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny

2021 Q1 Form 10-Q Financial Statement

#000117867021000017 Filed on April 29, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALNY ALNYLAM PHARMACEUTICALS, INC. Stock $alny

2021 Q1 Form 10-Q Financial Statement

#000117867021000017 Filed on April 29, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny